Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1864792 | 1.00 | NAAA (0.58) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL7004130 | 1.00 | NAAA (0.58) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL7672090 | 0.98 | NAAA (0.55) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL872365 | 0.93 | ALDH1A1 (0.48) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL6948951 | 0.85 | ALDH1A1 (0.39) | NAAAFAAHNPSR1DGKATSHR | |
| SCHEMBL9693869 | 0.83 | NAAA (0.55) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL11184931 | 0.81 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL5067226 | 0.81 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL5497221 | 0.81 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL9098367 | 0.81 | NAAA (0.52) | NAAAFAAHEPHX1RAD52NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129256-B2 | Antiparkinsonism drugs | SHIONOGI & CO., LTD. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20030191120-A1 | Antiparkinsonism drugs | SHIONOGI & CO., LTD. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1321151-A1 | ANTIPARKINSONISM DRUGS | SHIONOGI & CO., LTD. (JP) | 2003-06-25 | — | — | EP | disclosed |
| US-6319902-B1 | TO ACTIVATE THE CENTRAL NERVOUS SYSTEM, SUCH AS, FOR EXAMPLE, SUSTAINED ACETYLCHOLINE RELEASING ACTION, ANTI-RESERPINE ACTION AND LOCOMOTOR INCREMENT | SHIONOGI & CO., LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-0933379-A1 | NOVEL PEPTIDE DERIVATIVES HAVING THIAZOLYL-ALANINE RESIDUE | SHIONOGI & CO., LTD. (JP) | 1999-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191120-A1 | Antiparkinsonism drugs | PARK7, SNCA, NLN | NAAA 1167/4885FAAH 1462/4885EPHX1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.